Biogen (BIIB)
(Delayed Data from NSDQ)
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Zacks News
How Will Biotech ETFs React to Q4 Earnings?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.
Biogen (BIIB) Q4 Earnings Miss, Revenues Surpass Estimates
by Zacks Equity Research
Biogen's (BIIB) earnings lag estimates in the fourth quarter of 2020, while revenues surpass the same. Tecfidera generics continues to hurt sales. The company provides revenues guidance for 2021.
Biotech Stock Roundup: AMGN, VRTX Q4 Results, SAVA's Encouraging Drug Data & More
by Zacks Equity Research
Earnings of leading biotechs like Amgen (AMGN) and Vertex (VRTX) and vaccine updates from Novavax (NVAX) were some of the highlights of the biotech sector last week.
Cassava (SAVA) Soars on Encouraging Alzheimer's Study Data
by Zacks Equity Research
Cassava's (SAVA) Alzheimer's disease candidate, simufilam, improved cognition and behavior scores following six months of treatment in an open-label clinical study.
Biogen Inc. (BIIB) Misses Q4 Earnings Estimates
by Zacks Equity Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of -7.10% and 1.22%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion (ALXN) is set to provide updates on revenues and earnings when it releases fourth-quarter 2020 results on Feb 4.
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4?
by Zacks Equity Research
Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports fourth-quarter earnings.
Why the Earnings Surprise Streak Could Continue for Biogen Inc. (BIIB)
by Zacks Equity Research
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biohaven (BHVN) Falls as Troriluzole Fails in Alzheimer's Study
by Zacks Equity Research
Biohaven (BHVN) announces preliminary data from a phase II/III AD study demonstrating troriluzole's failure to achieve statistical improvement in primary endpoints.
The Zacks Analyst Blog Highlights: PayPal, Exxon Mobil, Goldman Sachs, Charter Communications and Biogen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PayPal, Exxon Mobil, Goldman Sachs, Charter Communications and Biogen
Top Research Reports for PayPal, Exxon Mobil & Goldman Sachs
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including PayPal (PYPL), Exxon Mobil (XOM), and Goldman Sachs (GS).
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic
by Ekta Bagri
The focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position NVAX, HALO and BPMC to outperform.
Diamondback Energy, Ryman Hospitality Properties, Eli Lilly, Biogen and Roche highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Diamondback Energy, Ryman Hospitality Properties, Eli Lilly, Biogen and Roche highlighted as Zacks Bull and Bear of the Day
Lilly's (LLY) Alzheimer's Drug Promising in Mid-Stage Study
by Zacks Equity Research
Lilly (LLY) announces data from a phase II study on its Alzheimer's disease candidate, donanemab, which shows slowing of cognitive decline.
Apple (AAPL), Biogen to Track Cognitive Health via Wearables
by Zacks Equity Research
Apple (AAPL) is collaborating with Biogen to test whether the Apple Watch and iPhone can collect and transmit biometric data on cognitive performance.
AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Disease Studies
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi achieves improvements in clinical remission and endoscopic response in phase III studies in moderate to severe Crohn's disease patients.
AbbVie's (ABBV) Skyrizi Succeeds in Psoriatic Arthritis Studies
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi achieves improvements in disease activity across joint and skin symptoms in phase III studies in active psoriatic arthritis.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
AbbVie's (ABBV) Rinvoq Gets CHMP Nod for Two New Indications
by Zacks Equity Research
AbbVie (ABBV) gets positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rinvoq for treating active psoriatic arthritis and active ankylosing spondylitis.
Rocket Pharmaceuticals (RCKT) Surges on Encouraging Study Data
by Zacks Equity Research
Rocket Pharmaceuticals' (RCKT) AAV-based gene therapy candidate demonstrates early evidence of clinical benefit and tolerability in patients with Danon disease, which affects the cardiac muscle.
AbbVie's (ABBV) Rinvoq Meets Goal in Ulcerative Colitis Study
by Zacks Equity Research
AbbVie's (ABBV) phase III U-ACHIEVE study evaluating Rinvoq for treating patients with moderate to severe ulcerative colitis achieves the primary goal. The study also met all secondary endpoints.
Biotech Stock Roundup: BIIB & SAGE Alliance, MRNA, BNTX Coronavirus Updates & More
by Zacks Equity Research
Collaborations, and pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and BioNTech (BNTX) provide key updates.
Biogen (BIIB) & Sage Therapeutics Partner for Depression Therapies
by Zacks Equity Research
Biogen (BIIB) and Sage Therapeutics (SAGE) collaborate to develop latter's zuranolone for depression indications and SAGE-324 for essential tremor.
Sanofi (SNY) Blood Disorder Candidate Gets FDA's Rejection
by Zacks Equity Research
The FDA gives a complete response letter to Sanofi's (SNY) regulatory application for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease.
Is a Beat in Store for Royalty Pharma (RPRX) in Q3 Earnings?
by Zacks Equity Research
Some of the drugs under Royalty Pharma's (RPRX) royalty acquisition agreements performed well during the third quarter while others declined or flatlined.